Tome Biosciences files notice to lay off virtually entire staff

High-profile gene editing startup Tome Biosciences said in a legal filing Friday that it will terminate virtually its entire staff beginning Nov. 1.

The Massachusetts WARN notice comes a day after STAT reported the company was in dire straits, with one source saying that it planned to wind down operations and seek a buyer by Nov. 1 after the company struggled to raise money or find a partner.

Tome told STAT it was only “operating at reduced capacity,” while  “maintaining core expertise” as it “explore[d] strategic options.”  

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In